美國(guó)ICPE規(guī)定的主藥和輔料的管理-David-R.-Schoneker_第1頁
美國(guó)ICPE規(guī)定的主藥和輔料的管理-David-R.-Schoneker_第2頁
美國(guó)ICPE規(guī)定的主藥和輔料的管理-David-R.-Schoneker_第3頁
美國(guó)ICPE規(guī)定的主藥和輔料的管理-David-R.-Schoneker_第4頁
美國(guó)ICPE規(guī)定的主藥和輔料的管理-David-R.-Schoneker_第5頁
已閱讀5頁,還剩55頁未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

IPECActivitiesandExcipientRegulationintheUnitedStatesPresentationtoSFDADavidR.SchonekerDirectorofGlobalRegulatoryAffairsOctober13,20041OutlineIPECBackgroundIPECGuidelinesandInitiativesExcipient&ColorantRegulationintheU.S.ExcipientMasterFilesExcipientQualificationProcessPharmacopeialHarmonizationPre-mixedExcipientsSUPAC&PostApprovalChanges2WhatisIPEC?3WhatisIPEC?4Colorcon’sInvolvementwithIPECColorconwasafoundingmemberofIPECColorconisafullmemberinIPECAmericas,IPECEurope,andJPECColorconactivelyparticipatesinthefollowingIPECCommittees:ExecutiveCompendialReview–HarmonizationWorkingGroupsGMPExcipientQualificationRegulatoryAffairsManyCommitteesarechairedbyColorconpersonnel5IPECMission6BuildingBridgeswithRegulators

IPECisactivelymeetingwithhighleveldirectorsatFDA,EMEA,MHLW,USP,PhEur,andJP/JPEtodiscussmanytopicsrelatedtoexcipientsRegulatoryRepresentativesroutinelyparticipateinIPECprojectsasadvisorsIPECprovidestechnicalassistanceandpracticalexperience7ExcipientGMPsintheU.S.U.S.FD&CActstatesthatcomponentsofdrugs(ie;excipients)shouldbemadeusing“appropriate”GMPsThereisnoactualregulationwhichdefineswhatisthe“appropriate”levelofGMPforpharmaceuticalexcipientsFDAdoesNOTroutinelyinspectexcipientmanufacturers;only“forcause”8ExcipientGMPsintheU.S.9IPECExcipientGMP’s10IPECExcipientGMP’s11PublishedIPEC-AmericasGuidelines

12IPECInitiatives13IPECInitiativesDevelopingGuidelinesforExcipientQualificationIncludesboththeUser’sandMaker’sperspectiveDevelopmentofStandardQuestionnairetemplatesThirdPartySupplierAssessment(IPEA)IPEAprovidesassessmentsofexcipientmanufacturingfacilitiesvs.IPECGMPIPEAAudits()14CurrentIPEAAuditReportsReportsReportNumberExcipientChemical/

CompendiaNameManufacturerLocationExcipientTradeNameEQ-01Alcohol,USPEquistarIllinois,USAEthylAlcoholEQ-02Alcohol,USP:denaturing&packagingEquistarNewJersey,USADenaturing&packagingPendingHydroxypropylatedStarchNFPendingPendingPendingPendingCarrageenanNFPendingPendingPendingCPK-01XanthanGumNFCPKelcoOklahoma,USAXantural180NS-01DisodiumSuccinateHexahydrateNipponShokbaiHimeji,JapanSS-50PQ-01SulfuricAcidNFProductosQuimicosNeuvoLeon,MexicoSulfuricAcidSE-01DisodiumSuccinateHydrateShivaEnterprisesPune,IndiaSodiumSuccinateHydratePendingMagnesiumSilicateNFPendingUSAPendingCL-01SodiumHydroxideNFCantonLaboratoriesVadodara,IndiaSodiumHydroxide15UseofExcipientsinNDA’s

intheU.S.FD&CActstatesthatexcipients(otherthancolors)mustmeetUSP/NFrequirementsifamonographexistsUSP/NFexcipientsdonotrequiresubmissionofsignificantqualityinformationwithNDA’s.However,functionalityinformationmaybenecessarybasedontheapplication16UseofExcipientsinNDA’s

intheU.S.17

U.S.GenericApplicationsForU.S.genericdrugapplications,allingredientsneedtobelistedintheFDA’sInactiveIngredientDatabase(formerlyknownastheInactiveIngredientGuideorIIG)ThelevelsofuseofeachexcipientinthedosageformmustbebelowlevelsexperiencedinpreviouslyapproveddrugsIfnot,safetydatamaybeneeded18

U.S.GenericApplications1920GlobalCOLORANTRegulationsForPharmaceuticalsUnitedStates-21CFR(Parts70-82)Europe-ECDirectives78/25/EEC and81/464/EECJapan-MinisterialOrdinanceNo.30(August

31,1966),JP,JPE,JPED,PrecedentListWHO-JECFARequirementsIndividualCountriesmayhaveuniquerequirementsandrestrictionsbasedonlocalrequirements21OneColorForTheWorld:

GlobalFormulationProblemsListofacceptablecolorsvariesSpecificationsaredifferentforthesamecolorantsColorsandspecificationsfornutritionalsupplementsvs.pharmaceuticalsaresometimesdifferentUserestrictionsmayapplyandmayvaryTheseissuescauseonlyafewcolorstobeavailableforinternationalformulations….22KeyColorsUsedInGlobalPharmaceuticalsFD&CBlue#1FD&CYellow#6TitaniumDioxideRedIronOxideYellowIronOxideBlackIronOxide23DesiredGlobalColorRegulationsCurrently,thereisnoharmonizationprocessforcolorsEachcountrymaintainstheirownlistsofapprovedcolorswhichcreatesglobaldevelopmentproblemsShouldbebasedprimarilyonsafetyUseofJECFAfoodcolorlistasaglobalstandardwouldbeveryhelpful!!!24DrugMasterFiles25USDMFFacts(J.Clark,FDA,2003)

March31,2003:16481DMFsonfile“Inactive”presumablymeansnoLOA/annualreport recentlysubmitted26USDMFFilings,2002(J.Clark,FDA,2003)DMFs DMFs/yearAll 585TypeII 358TypeIII 172TypeIV 51TypeV 427DrugMasterFileRequirements

Specifiedin1989guidancedocumentDMFTypesI.Manufacturingsite,facilitiesII.Drugsubstance,intermediate,drug

productIII.PackagingmaterialIV.Excipient,colorant,flavor,etc.V.FDAAcceptedReferenceInformation28TypeIVDMFInformationRequirements29IPECProposals:

Global“ExcipientMasterFiles”ExcipientMasterFile,astandardformatforsubmittinginformationIPECguidancepublished2004UnderconsiderationatFDASimplifyfilingprocessApplicabletoallexcipientsStandardformatandinformationrequirementsGlobalsubmissionsSimplifyreviewprocessStandardformatandinformationrequirements30ExcipientMasterFiles:ConsistentwithCTDSubmissionsWouldcontainallinformationrequiredinSectionP4ofCTDP4.1Specifications(Q6B)P4.2AnalyticalProcedures(Q2A,Q6B)P4.3ValidationofAnalyticalProcedures(Q2A,Q2B,Q6B)P4.4JustificationofSpecifications(Q3C,Q6B)P4.5ExcipientsofHumanorAnimalOrigin(Q5A,Q5D,Q6B)P4.6NovelExcipients31ExcipientMasterFileComponents32EMFOrganizationSummariesTechnicalReportsandDataRegionalInfoCoreTechnicalDocumentAdministrativeSection33TheIncreasingVisibilityofExcipients

ImpactoftheHaitiglycerindisasterCounterfeitDrugsandBioterrorismFutureneeds:WideinternationalacceptancetofacilitatethedesignofglobalpharmaceuticalformulationsAssurethatappropriateGMPandqualitystandardsareappliedtothedesignandmanufactureofthesematerialsForregulatoryagenciestogainabetterunderstandingofthepurposeandfunctionalityofexcipientsindrugformulations34Qualificationof

ExcipientSuppliers35SupplierQualification36IPECExcipientQualificationGuidelineCurrentProject37ExcipientQualification

Guideline3839ExcipientQualification

Process-User4041PharmacopeialHarmonization4243HarmonizationofExcipientStandardsPharmacopeiasUsersManufacturersRegulatory44Today’sHarmonizationOutcomes45ChinesePharmacopeiaCantheChinesePharmacopeia(CP)beharmonizedwiththeUSP?CanUSPgradeexcipientsbeusedinChinesedrugapplicationsifaCPmonographexists?ArethereanyGMPrequirementsforexcipientswhichcomplywithChinesePharmacopeiamonographs46ProductFilingInformation

Pre-MixedExcipients47ProductFilingInformation

Pre-mixedExcipientsTypicalinformationRequired:ProductcodenumberListofcomponents(chemicalnamesincludingviscosity/MWinformation)QuantitativepercentagesforeachcomponentGradeofeachcomponent(USP/NF,PhEur,JP/JPE,CFR,FCC,ECDirective,etc.)Evidenceofprioruseofeachcomponentinoralapplicationsatsimilarlevels4849DrugMasterFiles

Pre-mixedExcipients50Post-ApprovalChanges

UnitedStatesGuidanceforIndustry:ChangestoanApprovedNDAorANDA

ComponentandCompositionsectionrefersbacktoSUPAC(ScaleUpandPostApprovalChanges)guidancesSUPACcanbeusedtomakecertainchangesinexcipientlevelsMinorChangesareLevel1-AnnualReport,nopriorapprovalSUPACcoversdeletionofacolororflavorasaLevel1changeSUPACalsoallowsforadditionofanimprintcodeorqualitativechangesinprintinginksasa

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論